Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Where Will AbbVie Be in 3 Years?

TheMotleyFool

0 0

In spite of market turmoil, this year has been bright so far for AbbVie (NYSE: ABBV). The stock defied the bear market -- and even gained more than 6%.

The company's star drug Humira continues to grow, and even reached the milestone of more than $20 billion in sales last year. Its other immunology drugs and the neuroscience business also are thriving.

However, there's one big problem on the horizon for AbbVie: Humira is set to face competition, as of next year. AbbVie hasn't yet forecast future sales for Humira, but it's clear declines are ahead. Considering this, where will AbbVie be in about three years? Let's find out.

Source Fool.com

Like: 0

ABBV

Teilen